Tobias Feuchtinger

Prof. Dr. Tobias Feuchtinger serves as Professor and research leader at the Medical Center – University of Freiburg, holding dual strategic roles as Coordinator of the Bridging Topic "Cell and Gene Therapies of Infectious Diseases" and Deputy Coordinator for "Infections of the Immunocompromised Host". His work addresses critical mortality risks from viral infections in severely immunocompromised patients, particularly following allogeneic hematopoietic stem cell transplantation.

Research focus spans:

• Engineering virus-specific T cell therapies for CMV, EBV, and Adenovirus
• Overcoming donor serostatus limitations via seronegative adoptive transfer
• CRISPR/Cas-mediated development of dexamethasone-resistant immunotherapies
• Translational applications in hematopoietic stem cell transplant complications

His 2025 publication in Experimental Hematology and Oncology demonstrates integrated T cell engineering combining EBV-gp350 CAR targeting with glucocorticoid resistance—a breakthrough enabling concurrent immunosuppressant therapy and antiviral treatment. Current work emphasizes clinical translation of these engineered cellular products to reduce infection-related mortality.

Leadership responsibilities include:

• Coordinating cross-departmental "Bridging Topic" research initiatives
• Deputizing for the Infections of the Immunocompromised Host program
• Directing preclinical development of novel immunotherapies

While specific lab details aren't provided, his team operates within Freiburg's Medical Center focusing on translational immunotherapy development, with future work targeting multi-virus protection strategies and enhanced T cell persistence in immunosuppressed hosts.